Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Intrinsic Value
Shandong Weigao Group Medical Polymer Co. Ltd. engages in the research and development, production, and sale of medical devices. [ Read More ]
The intrinsic value of one
Shandong Weigao Group Medical Polymer Co Ltd
stock under the Base Case scenario is
9
HKD.
Compared to the current market price of 5.05 HKD,
Shandong Weigao Group Medical Polymer Co Ltd
is
Undervalued by 44%.
Shandong Weigao Group Medical Polymer Co Ltd's market capitalization is 23.1B HKD.
Shandong Weigao Group Medical Polymer Co Ltd stock price is 5.05 HKD.
Shandong Weigao Group Medical Polymer Co Ltd stock price (5.05 HKD) is 44% less than its Intrinsic Value (9 HKD).
Shandong Weigao Group Medical Polymer Co Ltd stock price (5.05 HKD) is 33% less than its DCF Value (7.53 HKD). Open DCF Valuation
Shandong Weigao Group Medical Polymer Co Ltd stock price (5.05 HKD) is 52% less than its Relative Value (10.47 HKD). Open Relative Valuation
Shandong Weigao Group Medical Polymer Co Ltd has upside potential of 91% compared to the average analyst price target.
Open Wall St Estimates
Shandong Weigao Group Medical Polymer Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
Shandong Weigao Group Medical Polymer Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 9%.
Shandong Weigao Group Medical Polymer Co Ltd's Revenue has dropped by 3% over the past 12 months.
Shandong Weigao Group Medical Polymer Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 9%.
Shandong Weigao Group Medical Polymer Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 12% to 9%.
Shandong Weigao Group Medical Polymer Co Ltd has positive three-year average ROE (Return on Equity): 12%. The company is efficient at transforming stockholders' equity into net income.
Shandong Weigao Group Medical Polymer Co Ltd has positive three-year average ROIC (Return on Invested Capital): 12%. The company is efficient at using invested capital to generate operating income.
Shandong Weigao Group Medical Polymer Co Ltd's Revenue has been growing by 4% per year for the last 3 years.
Shandong Weigao Group Medical Polymer Co Ltd's Revenue is forecast to grow at a rate of 6% per year over the next 3 years.
Shandong Weigao Group Medical Polymer Co Ltd has positive Net Income for the last twelve months.
Shandong Weigao Group Medical Polymer Co Ltd has positive Operating Income for the last twelve months.
Shandong Weigao Group Medical Polymer Co Ltd has positive Free Cash Flow for the last twelve months.
Shandong Weigao Group Medical Polymer Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (7B CNY) than debt (3B CNY).
Shandong Weigao Group Medical Polymer Co Ltd's Altman Z-Score is very high and is equal to 3.34.
Shandong Weigao Group Medical Polymer Co Ltd has positive Gross Profit for the last twelve months.
Shandong Weigao Group Medical Polymer Co Ltd's short-term assets (19B CNY) exceed its short-term liabilties (7B CNY).
Shandong Weigao Group Medical Polymer Co Ltd's long-term assets (34B CNY) exceed its long-term liabilties (12B CNY).
Shandong Weigao Group Medical Polymer Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.16.
Valuation Backtest
Shandong Weigao Group Medical Polymer Co Ltd
Run backtest to discover the historical profit from buying and selling
Shandong Weigao Group Medical Polymer Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Shandong Weigao Group Medical Polymer Co Ltd
Balance Sheet Decomposition
Shandong Weigao Group Medical Polymer Co Ltd
| Current Assets | 18.8B |
| Cash & Short-Term Investments | 7.1B |
| Receivables | 8B |
| Other Current Assets | 3.7B |
| Non-Current Assets | 15.2B |
| Long-Term Investments | 2.1B |
| PP&E | 7.3B |
| Intangibles | 5.5B |
| Other Non-Current Assets | 350.6m |
| Current Liabilities | 6.6B |
| Accounts Payable | 2B |
| Accrued Liabilities | 151.7m |
| Other Current Liabilities | 4.5B |
| Non-Current Liabilities | 5.3B |
| Long-Term Debt | 3.4B |
| Other Non-Current Liabilities | 1.9B |
Earnings Waterfall
Shandong Weigao Group Medical Polymer Co Ltd
|
Revenue
|
13.2B
CNY
|
|
Cost of Revenue
|
-6.6B
CNY
|
|
Gross Profit
|
6.6B
CNY
|
|
Operating Expenses
|
-4.1B
CNY
|
|
Operating Income
|
2.6B
CNY
|
|
Other Expenses
|
-556.9m
CNY
|
|
Net Income
|
2B
CNY
|
Free Cash Flow Analysis
Shandong Weigao Group Medical Polymer Co Ltd
Profitability Score
Profitability Due Diligence
Shandong Weigao Group Medical Polymer Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
Shandong Weigao Group Medical Polymer Co Ltd's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Shandong Weigao Group Medical Polymer Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Score
Shandong Weigao Group Medical Polymer Co Ltd's solvency score is 70/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Shandong Weigao Group Medical Polymer Co Ltd
According to Wall Street analysts, the average 1-year price target for
Shandong Weigao Group Medical Polymer Co Ltd
is 9.63 HKD
with a low forecast of 6.67 HKD and a high forecast of 17.85 HKD.
Shareholder Return
Price
Shandong Weigao Group Medical Polymer Co Ltd
| Average Annual Return | 25.32% |
| Standard Deviation of Annual Returns | 52.94% |
| Max Drawdown | -79% |
| Market Capitalization | 23.1B HKD |
| Shares Outstanding | 4 522 330 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Shandong Weigao Group Medical Polymer Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Shandong Weigao Group Medical Polymer Co. Ltd. engages in the research and development, production, and sale of medical devices. The company is headquartered in Weihai, Shandong. The company went IPO on 2004-02-27. The firm sells products under brand names of Jierui and Wego Ortho. The firm operates through three business segments. The Single Use Medical Device Products segment is engaged in the production and sale of single-use consumables, such as infusion sets, syringes, blood transfusion sets and blood bags. The Orthopaedic Products segment is engaged in the production and sale of orthopaedic products. The Blood Purification Products segment is engaged in the production and sale of blood purification products and related medical equipment. The firm is also engaged in the manufacture of industrial automatic equipment and parts, as well as the provision of logistics and storage services through its subsidiaries.
Contact
IPO
Employees
Officers
The intrinsic value of one
Shandong Weigao Group Medical Polymer Co Ltd
stock under the Base Case scenario is
9
HKD.
Compared to the current market price of 5.05 HKD,
Shandong Weigao Group Medical Polymer Co Ltd
is
Undervalued by 44%.
You don't have any saved screeners yet
